1 of 1
Story summary
- Todd Engel sued Novo Nordisk, alleging company failed to warn about NAION risk from Ozempic.
- JAMA Ophthalmology reported higher NAION rates among diabetic patients using semaglutide (Ozempic).
- FDA’s adverse-event database recorded over 1,000 optic-neuropathy reports linked to GLP-1 drugs since 2024.
- Novo Nordisk says NAION cases are rare, lack merit, and do not require label changes.
- The North American Neuro-Ophthalmology Society advises patients to continue GLP-1 therapy despite NAION concerns.